Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
Company profile
Ticker
HALO
Exchange
Website
CEO
Helen Torley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
Former names
GLOBAL YACHT SERVICES INC, HALOZYME THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Halozyme, Inc. • Antares Pharma, Inc • Antares Pharma IPL AG • Antares Pharma AG ...
IRS number
880488686
HALO stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Halozyme Provides Update on Licensee Co-formulation Patent Hearing In Europe
15 Mar 23
8-K
Other Events
13 Mar 23
8-K
Departure of Directors or Certain Officers
23 Feb 23
10-K
2022 FY
Annual report
21 Feb 23
8-K
Halozyme Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
21 Feb 23
8-K
Departure of Directors or Certain Officers
6 Feb 23
8-K
Halozyme Provides 2023 Financial Guidance and Outlook
10 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Halozyme Reports Third Quarter 2022 Financial and Operating Results
8 Nov 22
8-K
Entry into a Material Definitive Agreement
19 Aug 22
Transcripts
HALO
Earnings call transcript
2022 Q4
21 Feb 23
HALO
Earnings call transcript
2022 Q3
9 Nov 22
HALO
Earnings call transcript
2022 Q2
9 Aug 22
HALO
Earnings call transcript
2022 Q1
11 May 22
HALO
Earnings call transcript
2021 Q4
23 Feb 22
HALO
Earnings call transcript
2021 Q3
3 Nov 21
HALO
Earnings call transcript
2021 Q2
10 Aug 21
HALO
Earnings call transcript
2021 Q1
11 May 21
HALO
Earnings call transcript
2020 Q4
24 Feb 21
HALO
Earnings call transcript
2020 Q3
2 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
97.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 421 |
| Opened positions | 95 |
| Closed positions | 23 |
| Increased positions | 110 |
| Reduced positions | 171 |
| 13F shares | Current |
|---|---|
| Total value | 7.19 tn |
| Total shares | 132.29 mm |
| Total puts | 156.10 k |
| Total calls | 459.10 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 18.22 mm | $1.04 tn |
| Vanguard | 13.30 mm | $756.99 bn |
| Artisan Partners Limited Partnership | 7.14 mm | $406.32 bn |
| IVZ Invesco | 6.01 mm | $341.71 bn |
| STT State Street | 5.71 mm | $325.13 bn |
| Snyder Capital Management L P | 3.98 mm | $226.68 bn |
| BBBOF BB Biotech | 3.97 mm | $169.56 mm |
| William Blair Investment Management | 3.71 mm | $210.87 bn |
| JPM JPMorgan Chase & Co. | 3.23 mm | $183.65 bn |
| MCQEF Macquarie | 2.61 mm | $148.24 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Mar 23 | Torley Helen | Common Stock | Sell | Dispose S | No | Yes | 42.727 | 10,000 | 427.27 k | 623,666 |
| 9 Mar 23 | Torley Helen | Common Stock | Option exercise | Acquire M | No | Yes | 14.66 | 10,000 | 146.60 k | 633,666 |
| 9 Mar 23 | Torley Helen | Option to Purchase Common Stock Common Stock | Option exercise | Dispose M | No | Yes | 14.66 | 10,000 | 146.60 k | 0 |
| 8 Mar 23 | Torley Helen | Common Stock | Sell | Dispose S | No | Yes | 43.259 | 10,000 | 432.59 k | 623,666 |
| 8 Mar 23 | Torley Helen | Common Stock | Option exercise | Acquire M | No | Yes | 14.66 | 10,000 | 146.60 k | 633,666 |
| 8 Mar 23 | Torley Helen | Option to Purchase Common Stock Common Stock | Option exercise | Dispose M | No | Yes | 14.66 | 10,000 | 146.60 k | 10,000 |
| 7 Mar 23 | Torley Helen | Common Stock | Sell | Dispose S | No | Yes | 45.469 | 10,000 | 454.69 k | 623,666 |
| 7 Mar 23 | Torley Helen | Common Stock | Option exercise | Acquire M | No | Yes | 14.66 | 10,000 | 146.60 k | 633,666 |
| 7 Mar 23 | Torley Helen | Option to Purchase Common Stock Common Stock | Option exercise | Dispose M | No | Yes | 14.66 | 10,000 | 146.60 k | 20,000 |
| 1 Mar 23 | Torley Helen | Common Stock | Gift | Dispose G | No | No | 0 | 10,000 | 0.00 | 623,666 |
News
Wells Fargo Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $48
17 Mar 23
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
16 Mar 23
The Latest Analyst Ratings for Halozyme Therapeutics
16 Mar 23
SVB Leerink Downgrades Halozyme Therapeutics to Market Perform, Announces $42 Price Target
16 Mar 23
Wells Fargo Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $55
16 Mar 23
Press releases
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
15 Mar 23
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
21 Feb 23
Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results
7 Feb 23
Halozyme Appoints Barbara Duncan to its Board of Directors
6 Feb 23
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
11 Jan 23